Improving Preclinical Cancer Drug Development Models to Avoid Clinical Failure.

Area of Science:

• Oncology
• Pharmacology
• Translational Medicine

Background:

• Preclinical anti-cancer drug development frequently relies on cell cultures and animal models.
• These models often fail to predict clinical efficacy, leading to high attrition rates in drug development.
• Key differences in pharmacokinetics and the absence of immune system involvement in models contribute to this translational gap.

Purpose of the Study:

• To highlight limitations of current preclinical models in anti-cancer drug development.
• To identify factors that hinder the translation of preclinical findings to clinical success.
• To propose modifications for improving preclinical model utility and enhancing clinical translation.

Main Methods:

• Review and analysis of common preclinical models used in anti-cancer drug development.
• Examination of pharmacokinetic (ADME) and immunological differences between preclinical models and human patients.
• Discussion of existing literature and expert opinion on model limitations.

Main Results:

• Preclinical models often overestimate drug efficacy due to simplified biological systems and lack of human-specific factors.
• Pharmacokinetic (drug absorption, distribution, metabolism, excretion) differences between species are significant.
• The use of immune-deficient models excludes the critical role of the immune system in anti-cancer drug response.

Conclusions:

• Current preclinical models have significant limitations that impede the successful translation of anti-cancer drugs to the clinic.
• Modifications to preclinical models, incorporating human-relevant pharmacokinetics and immune system function, are necessary.
• Exploring alternative human cell-based and computer-based assays may improve the predictive power for clinical outcomes.